Andrew Donson
Concepts (417)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ependymoma | 26 | 2024 | 177 | 5.350 |
Why?
| Brain Neoplasms | 41 | 2025 | 1170 | 4.050 |
Why?
| Infratentorial Neoplasms | 7 | 2024 | 60 | 2.230 |
Why?
| Glioma | 15 | 2024 | 354 | 1.780 |
Why?
| Medulloblastoma | 15 | 2023 | 198 | 1.630 |
Why?
| Astrocytoma | 12 | 2023 | 122 | 1.600 |
Why?
| Gene Expression Regulation, Neoplastic | 26 | 2025 | 1354 | 1.570 |
Why?
| Glioblastoma | 14 | 2019 | 326 | 1.450 |
Why?
| Craniopharyngioma | 7 | 2024 | 82 | 1.430 |
Why?
| Brain Stem Neoplasms | 9 | 2023 | 89 | 1.370 |
Why?
| Gene Expression Profiling | 26 | 2024 | 1705 | 1.320 |
Why?
| Rhabdoid Tumor | 11 | 2025 | 98 | 1.190 |
Why?
| Cerebellar Neoplasms | 9 | 2023 | 156 | 1.180 |
Why?
| Pituitary Neoplasms | 5 | 2024 | 183 | 1.100 |
Why?
| Central Nervous System Neoplasms | 9 | 2021 | 149 | 0.930 |
Why?
| Ganglioglioma | 4 | 2017 | 31 | 0.800 |
Why?
| Biomarkers, Tumor | 12 | 2024 | 1181 | 0.790 |
Why?
| Proto-Oncogene Proteins B-raf | 5 | 2017 | 212 | 0.730 |
Why?
| Drug Screening Assays, Antitumor | 5 | 2021 | 195 | 0.730 |
Why?
| Cell Line, Tumor | 26 | 2025 | 3211 | 0.660 |
Why?
| Neoplastic Cells, Circulating | 1 | 2020 | 71 | 0.660 |
Why?
| Radiation Tolerance | 6 | 2022 | 100 | 0.650 |
Why?
| Transcriptome | 10 | 2023 | 885 | 0.650 |
Why?
| Neoplasm Recurrence, Local | 8 | 2021 | 959 | 0.650 |
Why?
| Single-Cell Analysis | 2 | 2021 | 276 | 0.610 |
Why?
| Child | 48 | 2024 | 20853 | 0.570 |
Why?
| Cyst Fluid | 1 | 2017 | 26 | 0.570 |
Why?
| Antineoplastic Agents | 7 | 2022 | 2058 | 0.540 |
Why?
| Oligonucleotide Array Sequence Analysis | 19 | 2016 | 768 | 0.510 |
Why?
| Radiation | 3 | 2021 | 24 | 0.510 |
Why?
| Teratoma | 6 | 2022 | 105 | 0.500 |
Why?
| Cell Cycle Proteins | 6 | 2022 | 586 | 0.490 |
Why?
| Humans | 100 | 2025 | 129212 | 0.470 |
Why?
| Chromosomes, Human, Pair 1 | 3 | 2020 | 71 | 0.470 |
Why?
| Cancer Vaccines | 2 | 2010 | 164 | 0.440 |
Why?
| DNA Methylation | 7 | 2021 | 607 | 0.430 |
Why?
| Child, Preschool | 29 | 2021 | 10507 | 0.410 |
Why?
| Tumor Microenvironment | 6 | 2023 | 634 | 0.400 |
Why?
| SMARCB1 Protein | 2 | 2025 | 29 | 0.390 |
Why?
| Radiation-Sensitizing Agents | 3 | 2016 | 40 | 0.380 |
Why?
| Cytokines | 4 | 2018 | 2011 | 0.370 |
Why?
| Neoplasm Proteins | 3 | 2012 | 424 | 0.360 |
Why?
| Cell Proliferation | 17 | 2022 | 2388 | 0.350 |
Why?
| Neoplasms, Neuroepithelial | 2 | 2021 | 17 | 0.350 |
Why?
| Survivors | 2 | 2023 | 463 | 0.350 |
Why?
| Tumor Suppressor Proteins | 2 | 2017 | 317 | 0.350 |
Why?
| Chromosome Aberrations | 2 | 2023 | 150 | 0.340 |
Why?
| Prognosis | 15 | 2023 | 3791 | 0.340 |
Why?
| Apoptosis | 14 | 2022 | 2501 | 0.330 |
Why?
| Supratentorial Neoplasms | 2 | 2021 | 19 | 0.330 |
Why?
| Histones | 4 | 2021 | 588 | 0.320 |
Why?
| Protein-Tyrosine Kinases | 4 | 2019 | 432 | 0.320 |
Why?
| Proto-Oncogene Proteins | 5 | 2022 | 637 | 0.310 |
Why?
| Microarray Analysis | 7 | 2017 | 122 | 0.310 |
Why?
| Oncogene Proteins, Fusion | 2 | 2021 | 201 | 0.310 |
Why?
| Quinazolines | 3 | 2022 | 244 | 0.310 |
Why?
| Pyrimidines | 6 | 2017 | 459 | 0.300 |
Why?
| Drug Resistance, Neoplasm | 5 | 2017 | 755 | 0.300 |
Why?
| Nuclear Proteins | 4 | 2017 | 663 | 0.290 |
Why?
| MAP Kinase Signaling System | 2 | 2021 | 311 | 0.290 |
Why?
| Mutation | 7 | 2021 | 3715 | 0.280 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2020 | 1565 | 0.280 |
Why?
| DNA Modification Methylases | 1 | 2007 | 15 | 0.280 |
Why?
| DNA Repair Enzymes | 1 | 2007 | 21 | 0.270 |
Why?
| Chemoradiotherapy | 2 | 2019 | 210 | 0.270 |
Why?
| Dacarbazine | 1 | 2007 | 94 | 0.270 |
Why?
| Antineoplastic Agents, Alkylating | 1 | 2007 | 69 | 0.270 |
Why?
| Cyclin-Dependent Kinase 6 | 2 | 2020 | 40 | 0.260 |
Why?
| Chromosomes | 2 | 2024 | 101 | 0.260 |
Why?
| B7-H1 Antigen | 2 | 2018 | 194 | 0.250 |
Why?
| Infant | 17 | 2020 | 9016 | 0.250 |
Why?
| RNA, Messenger | 8 | 2017 | 2702 | 0.250 |
Why?
| Immunohistochemistry | 6 | 2017 | 1696 | 0.250 |
Why?
| Tumor Cells, Cultured | 8 | 2019 | 939 | 0.250 |
Why?
| Chloroquine | 2 | 2017 | 52 | 0.250 |
Why?
| Sirtuin 2 | 1 | 2025 | 24 | 0.240 |
Why?
| Kaplan-Meier Estimate | 5 | 2021 | 857 | 0.240 |
Why?
| Cellular Senescence | 2 | 2024 | 181 | 0.230 |
Why?
| NF-kappa B | 2 | 2020 | 653 | 0.230 |
Why?
| DNA, Neoplasm | 2 | 2020 | 159 | 0.230 |
Why?
| Adolescent | 23 | 2021 | 20371 | 0.230 |
Why?
| Cisplatin | 3 | 2016 | 298 | 0.230 |
Why?
| Immunophenotyping | 2 | 2017 | 311 | 0.230 |
Why?
| Neoplasms, Radiation-Induced | 3 | 2010 | 71 | 0.230 |
Why?
| Molecular Targeted Therapy | 3 | 2018 | 389 | 0.220 |
Why?
| Male | 35 | 2024 | 63491 | 0.220 |
Why?
| Neurofibroma, Plexiform | 1 | 2023 | 9 | 0.220 |
Why?
| Pyrazoles | 5 | 2022 | 405 | 0.210 |
Why?
| Neurofibromatosis 1 | 1 | 2023 | 47 | 0.210 |
Why?
| Female | 35 | 2024 | 68600 | 0.210 |
Why?
| Autophagy | 2 | 2017 | 267 | 0.210 |
Why?
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2021 | 45 | 0.210 |
Why?
| Transcription Factors | 5 | 2023 | 1649 | 0.210 |
Why?
| Epigenesis, Genetic | 4 | 2021 | 613 | 0.200 |
Why?
| Survival Analysis | 3 | 2023 | 1271 | 0.200 |
Why?
| Indoles | 2 | 2017 | 383 | 0.200 |
Why?
| Tamoxifen | 2 | 2004 | 200 | 0.200 |
Why?
| Cell Survival | 8 | 2020 | 1085 | 0.190 |
Why?
| raf Kinases | 1 | 2021 | 11 | 0.190 |
Why?
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2021 | 16 | 0.190 |
Why?
| Sulfonamides | 2 | 2017 | 496 | 0.190 |
Why?
| Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 64 | 0.190 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 69 | 0.190 |
Why?
| Vaccination | 1 | 2010 | 1348 | 0.180 |
Why?
| Receptor, ErbB-3 | 2 | 2015 | 45 | 0.180 |
Why?
| Cohort Studies | 9 | 2021 | 5408 | 0.180 |
Why?
| Receptor, trkC | 1 | 2021 | 10 | 0.180 |
Why?
| Cell Cycle | 8 | 2017 | 590 | 0.180 |
Why?
| Mice | 13 | 2025 | 16861 | 0.180 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2023 | 202 | 0.180 |
Why?
| Gene Amplification | 1 | 2021 | 105 | 0.180 |
Why?
| Receptors, Fibroblast Growth Factor | 1 | 2021 | 65 | 0.180 |
Why?
| Receptor, trkB | 1 | 2021 | 30 | 0.180 |
Why?
| Gene Expression | 4 | 2015 | 1469 | 0.170 |
Why?
| Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 60 | 0.170 |
Why?
| Polycomb Repressive Complex 1 | 1 | 2020 | 47 | 0.170 |
Why?
| B7 Antigens | 1 | 2020 | 13 | 0.170 |
Why?
| Anilides | 2 | 2010 | 73 | 0.170 |
Why?
| DNA-Binding Proteins | 3 | 2021 | 1443 | 0.170 |
Why?
| Diagnosis, Computer-Assisted | 1 | 2020 | 87 | 0.170 |
Why?
| Cell Transformation, Neoplastic | 3 | 2019 | 328 | 0.160 |
Why?
| Phenotype | 5 | 2024 | 3074 | 0.160 |
Why?
| MicroRNAs | 2 | 2020 | 675 | 0.160 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2012 | 958 | 0.160 |
Why?
| Cell Lineage | 1 | 2021 | 333 | 0.160 |
Why?
| Machine Learning | 1 | 2024 | 443 | 0.160 |
Why?
| Genome, Human | 3 | 2021 | 393 | 0.160 |
Why?
| Lymphocytes, Tumor-Infiltrating | 2 | 2012 | 211 | 0.160 |
Why?
| Pteridines | 2 | 2016 | 22 | 0.150 |
Why?
| Infant, Newborn | 8 | 2020 | 5753 | 0.150 |
Why?
| Protein Kinase C | 1 | 2000 | 259 | 0.150 |
Why?
| Membrane Glycoproteins | 1 | 2021 | 473 | 0.150 |
Why?
| Aging | 2 | 2020 | 1774 | 0.150 |
Why?
| Dose-Response Relationship, Drug | 6 | 2017 | 2003 | 0.150 |
Why?
| ErbB Receptors | 2 | 2015 | 606 | 0.150 |
Why?
| Stromal Cells | 1 | 2018 | 107 | 0.150 |
Why?
| Meningioma | 2 | 2009 | 81 | 0.150 |
Why?
| Adenoviridae | 1 | 1998 | 192 | 0.140 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2022 | 511 | 0.140 |
Why?
| SOXE Transcription Factors | 2 | 2016 | 18 | 0.140 |
Why?
| Drug Approval | 1 | 2018 | 88 | 0.140 |
Why?
| Computer Simulation | 2 | 2021 | 941 | 0.140 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 2019 | 132 | 0.140 |
Why?
| Everolimus | 1 | 2017 | 86 | 0.140 |
Why?
| Receptors, Interleukin-6 | 1 | 2017 | 38 | 0.140 |
Why?
| Transcription Factor RelA | 1 | 2018 | 81 | 0.140 |
Why?
| Genes, p16 | 1 | 2017 | 19 | 0.140 |
Why?
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 54 | 0.140 |
Why?
| E2F Transcription Factors | 1 | 2017 | 59 | 0.140 |
Why?
| Spinal Neoplasms | 1 | 2017 | 29 | 0.140 |
Why?
| Morpholines | 1 | 2017 | 122 | 0.140 |
Why?
| Animals | 14 | 2025 | 35219 | 0.130 |
Why?
| Stem Cells | 1 | 2021 | 577 | 0.130 |
Why?
| Genetic Therapy | 1 | 1998 | 292 | 0.130 |
Why?
| Checkpoint Kinase 1 | 1 | 2016 | 31 | 0.130 |
Why?
| Retrospective Studies | 11 | 2020 | 14488 | 0.130 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2018 | 232 | 0.130 |
Why?
| Gene Expression Regulation, Developmental | 1 | 2021 | 820 | 0.130 |
Why?
| Image Processing, Computer-Assisted | 1 | 2020 | 742 | 0.130 |
Why?
| Bone Morphogenetic Proteins | 2 | 2019 | 131 | 0.130 |
Why?
| Blotting, Western | 6 | 2013 | 1205 | 0.130 |
Why?
| Myeloid Cells | 2 | 2015 | 143 | 0.130 |
Why?
| EGF Family of Proteins | 1 | 2015 | 17 | 0.120 |
Why?
| Young Adult | 9 | 2021 | 12396 | 0.120 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 431 | 0.120 |
Why?
| Neuroectodermal Tumors, Primitive | 2 | 2012 | 11 | 0.120 |
Why?
| Receptor, EphA2 | 1 | 2015 | 20 | 0.120 |
Why?
| Disease Models, Animal | 3 | 2021 | 4049 | 0.120 |
Why?
| Flow Cytometry | 3 | 2006 | 1156 | 0.120 |
Why?
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2015 | 22 | 0.120 |
Why?
| Pilomatrixoma | 1 | 2015 | 3 | 0.120 |
Why?
| Proteins | 1 | 2021 | 939 | 0.120 |
Why?
| Radiation, Ionizing | 2 | 2012 | 76 | 0.120 |
Why?
| Mutation, Missense | 1 | 2016 | 317 | 0.120 |
Why?
| Genetic Variation | 1 | 2019 | 937 | 0.110 |
Why?
| src-Family Kinases | 1 | 2015 | 96 | 0.110 |
Why?
| Follow-Up Studies | 6 | 2020 | 4886 | 0.110 |
Why?
| Activin Receptors, Type I | 1 | 2014 | 7 | 0.110 |
Why?
| Drug Delivery Systems | 2 | 2015 | 335 | 0.110 |
Why?
| Adult | 16 | 2023 | 35464 | 0.110 |
Why?
| Deoxyribose | 1 | 2013 | 6 | 0.110 |
Why?
| Glutamate-Cysteine Ligase | 1 | 2013 | 18 | 0.110 |
Why?
| STAT3 Transcription Factor | 1 | 2015 | 195 | 0.110 |
Why?
| RNA-Binding Proteins | 2 | 2015 | 387 | 0.100 |
Why?
| Survival Rate | 4 | 2020 | 1874 | 0.100 |
Why?
| Karyotyping | 4 | 2010 | 107 | 0.100 |
Why?
| Karnofsky Performance Status | 1 | 2012 | 38 | 0.100 |
Why?
| Acetylcysteine | 1 | 2013 | 146 | 0.100 |
Why?
| Exons | 1 | 2013 | 342 | 0.100 |
Why?
| Receptors, Opioid | 1 | 2012 | 21 | 0.100 |
Why?
| Isocitrate Dehydrogenase | 1 | 2012 | 52 | 0.100 |
Why?
| Pons | 1 | 2012 | 30 | 0.100 |
Why?
| Combined Modality Therapy | 4 | 2019 | 1202 | 0.100 |
Why?
| Cell Differentiation | 4 | 2025 | 1899 | 0.100 |
Why?
| Central Nervous System | 1 | 2014 | 255 | 0.100 |
Why?
| Tomography, X-Ray Computed | 2 | 2020 | 2525 | 0.100 |
Why?
| Protein Precursors | 1 | 2012 | 127 | 0.090 |
Why?
| Age Factors | 2 | 2017 | 3137 | 0.090 |
Why?
| Databases, Factual | 1 | 2016 | 1269 | 0.090 |
Why?
| Interleukin-6 | 1 | 2015 | 720 | 0.090 |
Why?
| RNA, Small Interfering | 2 | 2010 | 584 | 0.090 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2011 | 169 | 0.090 |
Why?
| Acetaminophen | 1 | 2013 | 246 | 0.090 |
Why?
| Protein Kinase Inhibitors | 3 | 2014 | 889 | 0.090 |
Why?
| Drug Synergism | 3 | 2017 | 369 | 0.090 |
Why?
| Risk Factors | 4 | 2020 | 9747 | 0.090 |
Why?
| Epigenomics | 2 | 2021 | 110 | 0.090 |
Why?
| Cluster Analysis | 3 | 2021 | 481 | 0.080 |
Why?
| Magnetic Resonance Imaging | 2 | 2020 | 3390 | 0.080 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2011 | 209 | 0.080 |
Why?
| Neoplasm Grading | 2 | 2021 | 285 | 0.080 |
Why?
| Poly(ADP-ribose) Polymerases | 1 | 2009 | 94 | 0.080 |
Why?
| Peripheral Nervous System Neoplasms | 1 | 2009 | 19 | 0.080 |
Why?
| Spinal Cord Neoplasms | 1 | 2009 | 40 | 0.080 |
Why?
| Astrocytes | 1 | 2011 | 199 | 0.080 |
Why?
| T-Lymphocytes | 2 | 2018 | 1928 | 0.080 |
Why?
| Hemangioma | 1 | 2009 | 44 | 0.080 |
Why?
| Proportional Hazards Models | 1 | 2012 | 1201 | 0.080 |
Why?
| Gene Ontology | 2 | 2021 | 51 | 0.080 |
Why?
| Kidney Neoplasms | 1 | 2013 | 350 | 0.080 |
Why?
| Enzyme Inhibitors | 4 | 2012 | 826 | 0.080 |
Why?
| Sarcoma, Ewing | 1 | 2009 | 89 | 0.070 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2010 | 231 | 0.070 |
Why?
| Glucose | 1 | 2013 | 1000 | 0.070 |
Why?
| Herpesvirus 3, Human | 1 | 2011 | 331 | 0.070 |
Why?
| Herpes Zoster | 1 | 2011 | 317 | 0.070 |
Why?
| Mesenchymoma | 1 | 2007 | 7 | 0.070 |
Why?
| Nerve Sheath Neoplasms | 1 | 2007 | 10 | 0.070 |
Why?
| DNA Copy Number Variations | 2 | 2021 | 170 | 0.070 |
Why?
| Meningeal Neoplasms | 1 | 2008 | 93 | 0.070 |
Why?
| Phosphorylation | 3 | 2017 | 1710 | 0.070 |
Why?
| Aurora Kinases | 3 | 2012 | 29 | 0.070 |
Why?
| Etoposide | 1 | 2007 | 148 | 0.070 |
Why?
| Real-Time Polymerase Chain Reaction | 3 | 2012 | 331 | 0.070 |
Why?
| Thymidine | 1 | 2006 | 59 | 0.070 |
Why?
| Aurora Kinase A | 3 | 2012 | 55 | 0.070 |
Why?
| Xenograft Model Antitumor Assays | 2 | 2019 | 813 | 0.070 |
Why?
| High Mobility Group Proteins | 1 | 2006 | 42 | 0.070 |
Why?
| Gene Silencing | 1 | 2007 | 187 | 0.060 |
Why?
| Dose-Response Relationship, Radiation | 2 | 2012 | 132 | 0.060 |
Why?
| Chromatin | 2 | 2020 | 479 | 0.060 |
Why?
| Piperazines | 2 | 2022 | 342 | 0.060 |
Why?
| Nerve Tissue Proteins | 1 | 2009 | 569 | 0.060 |
Why?
| Azepines | 2 | 2019 | 89 | 0.060 |
Why?
| Coculture Techniques | 2 | 2011 | 226 | 0.060 |
Why?
| In Situ Hybridization, Fluorescence | 3 | 2012 | 315 | 0.060 |
Why?
| Fatal Outcome | 2 | 2021 | 300 | 0.060 |
Why?
| Treatment Outcome | 3 | 2024 | 10189 | 0.060 |
Why?
| Computational Biology | 2 | 2020 | 597 | 0.060 |
Why?
| Pyrimidinones | 2 | 2016 | 103 | 0.060 |
Why?
| Benzamides | 2 | 2017 | 207 | 0.060 |
Why?
| Cell Division | 2 | 2010 | 796 | 0.060 |
Why?
| Signal Transduction | 2 | 2015 | 4913 | 0.060 |
Why?
| X-ray Repair Cross Complementing Protein 1 | 1 | 2023 | 14 | 0.050 |
Why?
| Intelligence Tests | 1 | 2023 | 58 | 0.050 |
Why?
| RNA, Small Nuclear | 1 | 2023 | 35 | 0.050 |
Why?
| Quality of Life | 1 | 2015 | 2693 | 0.050 |
Why?
| Cranial Irradiation | 1 | 2023 | 68 | 0.050 |
Why?
| Fluorouracil | 1 | 2024 | 199 | 0.050 |
Why?
| Proto-Oncogene Proteins c-sis | 1 | 2023 | 35 | 0.050 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2004 | 158 | 0.050 |
Why?
| Genomics | 2 | 2021 | 715 | 0.050 |
Why?
| Caspases | 1 | 2004 | 245 | 0.050 |
Why?
| Up-Regulation | 2 | 2016 | 837 | 0.050 |
Why?
| Cytidine Deaminase | 1 | 2023 | 57 | 0.050 |
Why?
| Membrane Proteins | 1 | 2009 | 1115 | 0.050 |
Why?
| Middle Aged | 7 | 2021 | 31075 | 0.050 |
Why?
| RNA | 2 | 2023 | 883 | 0.050 |
Why?
| Sequence Analysis, DNA | 2 | 2016 | 778 | 0.050 |
Why?
| Brain Stem | 1 | 2023 | 98 | 0.050 |
Why?
| Transcription, Genetic | 2 | 2021 | 1415 | 0.050 |
Why?
| G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 45 | 0.050 |
Why?
| Septum Pellucidum | 1 | 2021 | 5 | 0.050 |
Why?
| Sensitivity and Specificity | 1 | 2006 | 1834 | 0.050 |
Why?
| Pancreatic Neoplasms | 1 | 2009 | 879 | 0.050 |
Why?
| Cerebellum | 1 | 2023 | 218 | 0.050 |
Why?
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2021 | 14 | 0.050 |
Why?
| Ligands | 1 | 2023 | 621 | 0.050 |
Why?
| Mesencephalon | 1 | 2021 | 66 | 0.050 |
Why?
| Histone Deacetylases | 1 | 2023 | 210 | 0.050 |
Why?
| Drug Evaluation, Preclinical | 2 | 2013 | 171 | 0.050 |
Why?
| Chromosome Deletion | 1 | 2021 | 104 | 0.050 |
Why?
| Disease Progression | 2 | 2023 | 2622 | 0.050 |
Why?
| Neoplasm Staging | 2 | 2017 | 1292 | 0.050 |
Why?
| Genetic Heterogeneity | 1 | 2021 | 58 | 0.040 |
Why?
| DNA Damage | 2 | 2016 | 384 | 0.040 |
Why?
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2021 | 52 | 0.040 |
Why?
| Hedgehog Proteins | 1 | 2022 | 188 | 0.040 |
Why?
| Gene Rearrangement | 1 | 2021 | 148 | 0.040 |
Why?
| Metabolic Networks and Pathways | 1 | 2021 | 178 | 0.040 |
Why?
| Preoperative Period | 1 | 2020 | 114 | 0.040 |
Why?
| Vinblastine | 1 | 2020 | 69 | 0.040 |
Why?
| Cell Fusion | 1 | 2020 | 51 | 0.040 |
Why?
| Carboplatin | 1 | 2020 | 140 | 0.040 |
Why?
| Signal-To-Noise Ratio | 1 | 2020 | 68 | 0.040 |
Why?
| Repressor Proteins | 1 | 2023 | 406 | 0.040 |
Why?
| RNA, Neoplasm | 2 | 2009 | 88 | 0.040 |
Why?
| Cytotoxicity Tests, Immunologic | 1 | 1998 | 41 | 0.040 |
Why?
| Neuropsychological Tests | 1 | 2023 | 1006 | 0.040 |
Why?
| Mice, SCID | 1 | 2019 | 351 | 0.040 |
Why?
| Cell Self Renewal | 1 | 2019 | 53 | 0.040 |
Why?
| Pyridines | 2 | 2012 | 478 | 0.040 |
Why?
| Benchmarking | 1 | 2020 | 175 | 0.040 |
Why?
| Protein Isoforms | 1 | 2000 | 390 | 0.040 |
Why?
| Odontogenesis | 1 | 2018 | 11 | 0.040 |
Why?
| Laser Capture Microdissection | 1 | 2018 | 24 | 0.040 |
Why?
| Lysine | 1 | 2020 | 286 | 0.040 |
Why?
| In Vitro Techniques | 1 | 2020 | 1083 | 0.040 |
Why?
| Mice, Inbred NOD | 1 | 2019 | 588 | 0.040 |
Why?
| Tissue Culture Techniques | 1 | 2018 | 74 | 0.040 |
Why?
| Treatment Failure | 1 | 1999 | 339 | 0.040 |
Why?
| Receptors, HIV | 1 | 2017 | 26 | 0.040 |
Why?
| Mucin-1 | 1 | 2017 | 20 | 0.040 |
Why?
| Down-Regulation | 1 | 2000 | 636 | 0.040 |
Why?
| Cytogenetic Analysis | 1 | 2017 | 33 | 0.040 |
Why?
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 62 | 0.040 |
Why?
| Fluorescent Antibody Technique | 1 | 2018 | 376 | 0.040 |
Why?
| Triazoles | 1 | 2019 | 152 | 0.030 |
Why?
| Immune System | 1 | 1998 | 175 | 0.030 |
Why?
| Genetic Vectors | 1 | 1998 | 312 | 0.030 |
Why?
| Pituitary Gland | 1 | 2018 | 148 | 0.030 |
Why?
| HEK293 Cells | 1 | 2020 | 693 | 0.030 |
Why?
| Interleukin-2 | 1 | 1998 | 436 | 0.030 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 119 | 0.030 |
Why?
| Ki-67 Antigen | 1 | 2017 | 109 | 0.030 |
Why?
| Mice, Nude | 1 | 2019 | 683 | 0.030 |
Why?
| Glial Fibrillary Acidic Protein | 1 | 2017 | 92 | 0.030 |
Why?
| Neuroglia | 1 | 2018 | 167 | 0.030 |
Why?
| Models, Theoretical | 1 | 2020 | 543 | 0.030 |
Why?
| Cetuximab | 1 | 2017 | 94 | 0.030 |
Why?
| Benzodiazepinones | 1 | 2016 | 17 | 0.030 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2016 | 24 | 0.030 |
Why?
| Camptothecin | 1 | 2017 | 109 | 0.030 |
Why?
| Diagnosis, Differential | 2 | 2012 | 1424 | 0.030 |
Why?
| Genes, myc | 1 | 2016 | 50 | 0.030 |
Why?
| Immune Tolerance | 1 | 1998 | 354 | 0.030 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 487 | 0.030 |
Why?
| Urea | 1 | 2016 | 76 | 0.030 |
Why?
| Microscopy, Confocal | 1 | 2017 | 310 | 0.030 |
Why?
| Antigens, CD | 1 | 1998 | 488 | 0.030 |
Why?
| Mice, Transgenic | 1 | 2021 | 2111 | 0.030 |
Why?
| T-Lymphocytes, Regulatory | 1 | 1998 | 375 | 0.030 |
Why?
| Thiophenes | 1 | 2016 | 118 | 0.030 |
Why?
| Amino Acid Substitution | 1 | 2016 | 282 | 0.030 |
Why?
| Sequence Analysis, RNA | 1 | 2018 | 428 | 0.030 |
Why?
| Transcriptional Activation | 1 | 2017 | 365 | 0.030 |
Why?
| Amphiregulin | 1 | 2015 | 25 | 0.030 |
Why?
| Mitosis | 1 | 2016 | 179 | 0.030 |
Why?
| Recombinant Proteins | 1 | 1998 | 1303 | 0.030 |
Why?
| Cell Culture Techniques | 1 | 2017 | 345 | 0.030 |
Why?
| Gene Fusion | 1 | 2015 | 24 | 0.030 |
Why?
| HeLa Cells | 1 | 2016 | 607 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2016 | 647 | 0.030 |
Why?
| Lipopolysaccharide Receptors | 1 | 2015 | 87 | 0.030 |
Why?
| Aged | 4 | 2016 | 22030 | 0.030 |
Why?
| Gene Dosage | 1 | 2015 | 142 | 0.030 |
Why?
| Inhibitor of Differentiation Protein 1 | 1 | 2014 | 6 | 0.030 |
Why?
| Inhibitor of Differentiation Protein 2 | 1 | 2014 | 5 | 0.030 |
Why?
| Smad Proteins | 1 | 2014 | 38 | 0.030 |
Why?
| Imaging, Three-Dimensional | 1 | 2017 | 530 | 0.030 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2013 | 68 | 0.030 |
Why?
| Receptors, IgG | 1 | 2013 | 74 | 0.030 |
Why?
| Promoter Regions, Genetic | 1 | 2017 | 1206 | 0.030 |
Why?
| Algorithms | 1 | 2020 | 1618 | 0.030 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2013 | 137 | 0.030 |
Why?
| Phosphoproteins | 1 | 2015 | 331 | 0.030 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2013 | 329 | 0.030 |
Why?
| HLA-DR Antigens | 1 | 2013 | 224 | 0.020 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 398 | 0.020 |
Why?
| Catalysis | 1 | 2013 | 308 | 0.020 |
Why?
| Monocytes | 1 | 2015 | 551 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2020 | 3067 | 0.020 |
Why?
| Inflammation Mediators | 1 | 2015 | 505 | 0.020 |
Why?
| Colorado | 1 | 2022 | 4412 | 0.020 |
Why?
| Glutathione | 1 | 2013 | 348 | 0.020 |
Why?
| Tubulin | 1 | 2012 | 137 | 0.020 |
Why?
| Neural Stem Cells | 1 | 2012 | 143 | 0.020 |
Why?
| Acetylation | 1 | 2011 | 246 | 0.020 |
Why?
| RNA Interference | 1 | 2012 | 447 | 0.020 |
Why?
| Mice, Inbred C57BL | 1 | 2021 | 5408 | 0.020 |
Why?
| c-Mer Tyrosine Kinase | 1 | 2010 | 44 | 0.020 |
Why?
| Choroid Plexus Neoplasms | 1 | 2009 | 9 | 0.020 |
Why?
| Papilloma | 1 | 2009 | 46 | 0.020 |
Why?
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2009 | 13 | 0.020 |
Why?
| Zebrafish | 1 | 2014 | 458 | 0.020 |
Why?
| Kinetics | 1 | 2013 | 1641 | 0.020 |
Why?
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2009 | 42 | 0.020 |
Why?
| Immunoglobulin Heavy Chains | 1 | 2009 | 80 | 0.020 |
Why?
| Epilepsy | 1 | 2013 | 329 | 0.020 |
Why?
| Gene Knockdown Techniques | 1 | 2010 | 315 | 0.020 |
Why?
| Antibodies, Neoplasm | 1 | 2009 | 35 | 0.020 |
Why?
| Single-Blind Method | 1 | 2009 | 271 | 0.020 |
Why?
| Claudins | 1 | 2009 | 25 | 0.020 |
Why?
| Cytogenetics | 1 | 2008 | 12 | 0.020 |
Why?
| Virus Replication | 1 | 2011 | 450 | 0.020 |
Why?
| Leukocytes, Mononuclear | 1 | 2011 | 545 | 0.020 |
Why?
| DNA Repair | 1 | 2009 | 206 | 0.020 |
Why?
| Paresis | 1 | 2007 | 30 | 0.020 |
Why?
| Inflammation | 1 | 2018 | 2723 | 0.020 |
Why?
| Biopsy | 1 | 2010 | 1087 | 0.020 |
Why?
| Craniotomy | 1 | 2007 | 68 | 0.020 |
Why?
| Hypothalamic Neoplasms | 1 | 2006 | 9 | 0.020 |
Why?
| Microscopy, Electron | 1 | 2007 | 425 | 0.020 |
Why?
| Multigene Family | 1 | 2007 | 199 | 0.020 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2013 | 2071 | 0.020 |
Why?
| Vision Disorders | 1 | 2007 | 135 | 0.020 |
Why?
| Genetic Linkage | 1 | 2006 | 299 | 0.020 |
Why?
| Neural Crest | 1 | 2006 | 114 | 0.020 |
Why?
| Genetic Markers | 1 | 2006 | 338 | 0.020 |
Why?
| Data Interpretation, Statistical | 1 | 2007 | 335 | 0.020 |
Why?
| Caspase 3 | 1 | 2004 | 244 | 0.010 |
Why?
| Enzyme Activation | 1 | 2004 | 811 | 0.010 |
Why?
| Aged, 80 and over | 1 | 2013 | 7061 | 0.010 |
Why?
| Brain | 1 | 2013 | 2664 | 0.010 |
Why?
| Genetic Predisposition to Disease | 1 | 2006 | 2281 | 0.010 |
Why?
| Time Factors | 1 | 2008 | 6549 | 0.010 |
Why?
| Neoplasms | 1 | 2008 | 2467 | 0.010 |
Why?
|
|
Donson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|